Comparison of [¹⁸F]fluciclovine and [¹⁸F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients.

ABSTRACT:

Purpose

[¹⁸F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, [¹⁸F]FDG PET has some limitations, and imaging with alternative tracers should be explored. In this study, we aimed to evaluate the performance of [¹⁸F]fluciclovine PET compared to [¹⁸F]FDG PET in newly diagnosed MM patients.

Procedures

Thirteen newly diagnosed transplant eligible MM patients were imaged both with [¹⁸F]FDG PET/CT and [¹⁸F]fluciclovine PET/CT within 1 week in a prospective study. The subjects were visually assessed positive or negative for disease. The number of lesions and the SUV_max of selected lesions were measured for both tracers. Furthermo

SUBMITTER: Stokke C 

PROVIDER: S-EPMC9581841 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature